CD4 masking during human immunodeficiency virus type 1 infection, quantified on peripheral blood lymphocytes, is a potential marker of disease progression

J Infect Dis. 1996 Mar;173(3):565-73. doi: 10.1093/infdis/173.3.565.

Abstract

In human immunodeficiency virus type 1 (HIV-1)-infected adults, the proportion of gp120-free CD4 molecules on the surface of T lymphocytes was measured by double-epitope EIA and expressed as a CD epitope concentration ratio. In 51% of these patients (n=81), CD4 T cells showed a significant decrease (up to 100%) in the accessibility of the CD4 epitope in the D1 domain remained accessible. Of interest, a significant increase in the CD4 gp120 binding site concentration, without a change in T cell counts, was observed within 10 days after initiation of zidovudine treatment. Furthermore, CD4 masking by gp120 was associated with a poor clinical patient status. The assessment of the CD4 epitope concentration ratio is proposed as a surrogate marker of disease progression in HIV-1-infected patients.

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Biomarkers
  • CD4 Antigens / metabolism*
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / virology
  • Cell Membrane / immunology
  • Cell Membrane / virology
  • HIV Core Protein p24 / blood
  • HIV Envelope Protein gp120 / metabolism
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV Infections / virology
  • HIV-1*
  • Humans
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / virology
  • Zidovudine / therapeutic use

Substances

  • Antiviral Agents
  • Biomarkers
  • CD4 Antigens
  • HIV Core Protein p24
  • HIV Envelope Protein gp120
  • Zidovudine